Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
Adlai Nortye Ltd. has announced the dosing of the first patient in the United States in the intermittent weekly dosing arm of their Phase 1 global clinical trial for AN9025, their novel pan-RAS(ON) inhibitor targeting multiple RAS mutations in advanced solid tumors. The trial is evaluating safety and efficacy with both daily and weekly dosing sched…